Hypersplenism disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: HYP063 MIFTS: 53	Hypersplenism Categories: Blood diseases, Immune diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Hypersplenism

MalaCards integrated aliases for Hypersplenism:

Name: Hypersplenism ¹² ⁵⁴ ⁴³ ¹⁵ ¹⁷ ⁷¹ ³²

Hypersplenia ¹²

Classifications:

MalaCards categories:
Anatomical: Immune diseases Blood diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism

Other diseases of blood and blood-forming organs

Diseases of spleen

Hypersplenism

External Ids:

Disease Ontology ¹² DOID:6376

ICD9CM ³⁴ 289.4

MeSH ⁴³ D006971

NCIt ⁴⁹ C34714

SNOMED-CT ⁶⁷ 58381000

ICD10 ³² D73.1

EFO ¹⁷ EFO_1000975

UMLS ⁷¹ C0020532

Sources

Summaries for Hypersplenism

MalaCards based summary : Hypersplenism, also known as hypersplenia, is related to anemia, x-linked, with or without neutropenia and/or platelet abnormalities and esophageal varix. An important gene associated with Hypersplenism is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Tacrolimus and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include liver, spleen and bone, and related phenotypes are immune system and hematopoietic system

Wikipedia : ⁷⁴ Splenomegaly is an enlargement of the spleen. The spleen usually lies in the left upper quadrant (LUQ)... more...

Sources

Related Diseases for Hypersplenism

Diseases related to Hypersplenism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 570)

#	Related Disease	Score	Top Affiliating Genes
1	anemia, x-linked, with or without neutropenia and/or platelet abnormalities	31.0	FOXP3 EPO CSF3 ALB
2	esophageal varix	30.9	SERPINC1 GPT F2 ALB
3	splenic abscess	30.8	GPT F2 ALB
4	ileus	30.7	IFNG F2 CSF2
5	sickle cell anemia	30.7	F2 EPO CSF3 ALB
6	hemolytic anemia	30.6	IL4 IFNG F2 EPO CSF3
7	splenic infarction	30.6	SERPINC1 GPT F2 ALB
8	liver cirrhosis	30.4	THPO SERPINC1 GPT F2 ALB
9	paralytic ileus	30.4	GPT F2 ALB
10	endocarditis	30.3	SERPINC1 IFNG F2 ALB
11	q fever	30.3	TLR4 IL4 IFNG
12	mycobacterium tuberculosis 1	30.3	TLR4 IL4 IFNG CD4
13	sarcoidosis 1	30.3	LTA IL2RA IFNG CD4
14	portal hypertension	30.2	TLR4 THPO GPT F2 CD4 ALB
15	hepatoportal sclerosis	30.2	GPT F2
16	paroxysmal nocturnal hemoglobinuria	30.2	SERPINC1 F2 CSF3
17	schistosomiasis	30.2	IL4 IFNG GPT F2 ALB
18	biliary atresia	30.1	IFNG GPT F2 ALB
19	peripheral vascular disease	30.1	SERPINC1 F2 EPO ALB
20	splenic sequestration	30.1	THPO F2 EPO CD4
21	hepatic encephalopathy	30.1	GPT F2 ALB
22	brucellosis	30.1	TLR4 IL4 IFNG
23	hepatic coma	30.1	SERPINC1 GPT F2 ALB
24	hepatorenal syndrome	30.0	GPT F2 ALB
25	peritonitis	30.0	TLR4 IL4 IFNG F2 CSF3 ALB
26	deficiency anemia	29.9	THPO SERPINC1 EPO BMP6 ALB
27	candidiasis	29.9	TLR4 IL4 IFNG CSF2
28	bilirubin metabolic disorder	29.9	GPT F2 ALB
29	aphthous stomatitis	29.9	TLR4 IL4 IFNG CSF2
30	purpura	29.9	THPO SERPINC1 IL4 IFNG F2
31	duodenal ulcer	29.8	TLR4 LTA EGF
32	thymoma	29.8	IL4 FOXP3 EGF CSF3
33	bacterial infectious disease	29.8	TLR4 IFNG CSF3 CSF2 CD4
34	dysentery	29.8	TLR4 GPT CD4 ALB
35	thrombocytopenia due to platelet alloimmunization	29.7	THPO FOXP3 CD4
36	hepatitis b	29.7	TLR4 IFNG GPT F2 ALB
37	toxic shock syndrome	29.6	TLR4 SERPINC1 LTA IL4 IFNG
38	abdominal tuberculosis	29.6	IFNG GPT F2 CD4 ALB
39	syphilis	29.6	IFNG GPT F2 CD4 ALB
40	acquired immunodeficiency syndrome	29.5	IL2RA IFNG EPO CSF2 CD4 ALB
41	mycosis fungoides	29.5	IL4 IL2RA IFNG FOXP3
42	stomatitis	29.4	TLR4 IL4 IFNG CSF3 CSF2 CD4
43	autoimmune hepatitis	29.4	IL4 GPT FOXP3 F2 ALB
44	lymphoma	29.3	REL LTA IL4 IL2RA CSF3 CSF2
45	visceral leishmaniasis	29.3	TLR4 LTA IL4 IFNG FOXP3 ALB
46	cholecystitis	29.3	TLR4 GPT F2 EGF ALB
47	myeloproliferative neoplasm	29.2	THPO EPO CSF3 CSF2
48	hemoglobinuria	29.2	THPO SERPINC1 F2 EPO CSF3
49	viral hepatitis	29.2	TLR4 IL4 IFNG GPT F2 ALB
50	heart disease	29.2	TLR4 SERPINC1 GPT F2 EPO CD4

Comorbidity relations with Hypersplenism via Phenotypic Disease Network (PDN): (show all 12)

Acquired Thrombocytopenia	Active Peptic Ulcer Disease
Acute Cystitis	Alcoholic Liver Cirrhosis
Chronic Congestive Splenomegaly	Deficiency Anemia
Heart Disease	Hepatic Encephalopathy
Iron Deficiency Anemia	Neutropenia
Portal Hypertension	Primary Thrombocytopenia

Graphical network of the top 20 diseases related to Hypersplenism:

Sources

Symptoms & Phenotypes for Hypersplenism

MGI Mouse Phenotypes related to Hypersplenism:

⁴⁵ (show all 16)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	immune system	MP:0005387	10.41	ALB CD4 CSF2 CSF3 EGF EPO
2	hematopoietic system	MP:0005397	10.4	CD4 CSF2 CSF3 EPO F2 FOXP3
3	homeostasis/metabolism	MP:0005376	10.35	ALB CD4 CSF2 EPO F2 FOXP3
4	cardiovascular system	MP:0005385	10.34	ALB CSF2 EPO F2 FOXP3 IFNG
5	cellular	MP:0005384	10.33	ALB CD4 CSF2 EPO F2 FOXP3
6	growth/size/body region	MP:0005378	10.32	BMP6 CD4 CSF2 EGF F2 FOXP3
7	endocrine/exocrine gland	MP:0005379	10.26	ALB CD4 CSF2 EGF FOXP3 IFNG
8	digestive/alimentary	MP:0005381	10.24	ALB CD4 EGF F2 FOXP3 IFNG
9	integument	MP:0010771	10.21	CD4 CSF2 CSF3 EGF EPO F2
10	mortality/aging	MP:0010768	10.21	ALB CD4 CSF2 EPO F2 FOXP3
11	liver/biliary system	MP:0005370	10.1	ALB EPO FOXP3 IFNG IL4 LTA
12	normal	MP:0002873	10.1	ALB CD4 EGF EPO F2 FOXP3
13	renal/urinary system	MP:0005367	9.86	ALB CSF2 CSF3 FOXP3 IFNG IL4
14	respiratory system	MP:0005388	9.85	CSF2 EPO F2 FOXP3 IFNG IL2RA
15	skeleton	MP:0005390	9.7	BMP6 CSF2 EPO F2 GPT IFNG
16	vision/eye	MP:0005391	9.32	EGF FOXP3 IFNG IL2RA IL4 LTA

Sources

Drugs & Therapeutics for Hypersplenism

Drugs for Hypersplenism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Tacrolimus

Approved, Investigational

Phase 4

104987-11-3

445643 439492 6473866

Mycophenolic acid

Approved

Phase 4

24280-93-1

446541

Heparin

Approved, Investigational

Phase 4

9005-49-6

46507594 772

Warfarin

Approved

Phase 4

81-81-2

6691 54678486

Dalteparin

Approved

Phase 4

9005-49-6

Nadroparin

Approved, Investigational

Phase 4

Dipyridamole

Approved

Phase 4

58-32-2

3108

tannic acid

Approved

Phase 4

1401-55-4

Tinzaparin

Approved

Phase 4

9041-08-1, 9005-49-6

25244225

Aspirin

Approved, Vet_approved

Phase 4

50-78-2

2244

Benzocaine

Approved, Investigational

Phase 4

94-09-7, 1994-09-7

2337

Liver Extracts

Phase 4

Anti-Bacterial Agents

Phase 4

Antibiotics, Antitubercular

Phase 4

Antitubercular Agents

Phase 4

Analgesics, Non-Narcotic

Phase 4

Phosphodiesterase Inhibitors

Phase 4

Fibrinolytic Agents

Phase 4

Anticoagulants

Phase 4

Cyclooxygenase Inhibitors

Phase 4

Heparin, Low-Molecular-Weight

Phase 4

Platelet Aggregation Inhibitors

Phase 4

Analgesics

Phase 4

Antipyretics

Phase 4

Vasodilator Agents

Phase 4

Calcium, Dietary

Phase 4

calcium heparin

Phase 4

Anti-Inflammatory Agents, Non-Steroidal

Phase 4

Calcium

Nutraceutical

Phase 4

7440-70-2

271

Epirubicin

Approved

Phase 1, Phase 2

56420-45-2

41867

Cyclophosphamide

Approved, Investigational

Phase 1, Phase 2

50-18-0, 6055-19-2

2907

Valproic acid

Approved, Investigational

Phase 1, Phase 2

99-66-1

3121

Lenalidomide

Approved

Phase 2

191732-72-6

216326

Melphalan

Approved

Phase 2

148-82-3

460612 4053

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239 406563

Tegafur

Approved, Investigational

Phase 2

17902-23-7

5386

Neurotransmitter Agents

Phase 1, Phase 2

Psychotropic Drugs

Phase 1, Phase 2

Anticonvulsants

Phase 1, Phase 2

Alkylating Agents

Phase 2

Angiogenesis Inhibitors

Phase 2

Protein Kinase Inhibitors

Phase 2

Antimetabolites

Phase 2

Gemcitabine

Approved

95058-81-4

60750

Carboplatin

Approved

41575-94-4

10339178 38904 498142

Oprelvekin

Approved, Investigational

145941-26-0

Cisplatin

Approved

15663-27-1

2767 441203 84093

Fluorouracil

Approved

51-21-8

3385

Ethiodized oil

Approved, Investigational

8008-53-5

Rivaroxaban

Approved

366789-02-8

Interventional clinical trials:

(show all 24)

#	Name	Status	NCT ID	Phase	Drugs
1	Comparison Of Efficacy Of Two Immunosuppressive Protocols Including Tacrolimus With Or Without Mycophenolate Mofetil In Pediatric Liver Transplantation Aimed In Early Termination Of Steroid Therapy	Completed	NCT00195988	Phase 4	tacrolimus, steroids, mycophenolate mofetil
2	Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy	Recruiting	NCT02238444	Phase 4	Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
3	Autologous Bone Marrow Stem Cells Infusion Through Hepatic Artery in Open Abdominal Portal Hypertension Surgery for the Treatment of Liver Cirrhosis: a Prospective, Non-randomized, Controlled Study	Unknown status	NCT01560845	Phase 2, Phase 3
4	A Prospective Phase II Randomized, Blinded Study to Demonstrate the Effectiveness of Jobelyn for the Treatment of Breast Cancer Patients.	Unknown status	NCT01936064	Phase 1, Phase 2	Placebo + Cyclophosphamide - Epirubicin 6
5	An Open Label Multicenter Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 in Adult Subjects With Liver Dysfunction Due to Lysosomal Acid Lipase Deficiency Who Previously Received Treatment in Study LAL-CL01	Completed	NCT01488097	Phase 2	sebelipase alfa
6	An Open-Label Multicenter Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SBC-102 in Adult Participants With Liver Dysfunction Due to Lysosomal Acid Lipase Deficiency	Completed	NCT01307098	Phase 1, Phase 2	Sebelipase alfa 0.35 mg/kg;Sebelipase alfa 1 mg/kg;Sebelipase alfa 3 mg/kg
7	Pilot (Phase I-II) Study of Valproic Acid (Depakote) for the Treatment of the Autoimmune Lymphoproliferative Syndrome (ALPS)	Completed	NCT00605657	Phase 1, Phase 2	Valproic Acid
8	Revlimid®, and Metronomic Melphalan in the Management of Higher Risk Myelodysplastic Syndromes (MDS) and CMML: A Phase 2 Study"	Completed	NCT00744536	Phase 2	Lenalidomide and melphalan
9	Phase 1 Clinical Trial Using Mesenchymal Stem Cell and Regulatory T Cells as Individualized Medicine to Evaluate the Safety and Efficacy in End-stage Liver Disease	Not yet recruiting	NCT03460795	Phase 1, Phase 2
10	A Phase II Trial of Sorafenib Plus Tegafur-uracil (UFT) vs. Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation &/or TACE	Terminated	NCT01539018	Phase 2	Sorafenib;sorafenib plus tegafur-uracil
11	Hypersplenism in Patients With Liver Cirrhosis and Portal Hypertension: Prevalence, Pattern, Correlations, and Therapy	Unknown status	NCT03269877
12	Comparative Study of Microwave Ablation and Partial Splenic Embolization in the Management of Hypersplenism	Unknown status	NCT02261584
13	Multicentric Retrospective Case Control Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis	Unknown status	NCT01201655
14	Management of Childhood Pancytopenia in Heamatology Unit in Assiut University Hospital	Unknown status	NCT03521947
15	The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLC Receiving Gemcitabine and Cisplatin or Carboplatin Chemotherapy	Unknown status	NCT02344979
16	Gall Bladder Status Among Children With Chronic Haemolytic Anemia Attending to Assuit University Children Hospital	Unknown status	NCT03533322
17	A Randomized Controlled Trial of Treatment of Portal Vein Tumor Thrombus After Hepatocellular Carcinoma Resection	Completed	NCT00825669		TACE
18	The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia. Clinical Presentation and Follow up. Splenectomy, Indications and Complications.	Completed	NCT00971698
19	Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic Portal Vein Thrombosis in HCV Related Compensated Cirrhosis	Completed	NCT03201367		Rivaroxaban
20	The Treatment of Gastroesophageal Varices Accompanied With Splenomegaly or Hypersplenism of Hepatocirrhosis and Portal Hypertension	Recruiting	NCT02778425
21	Differential Diagnostic of ITP and MDS: a Prospective Study by Next‐Generation Flow Cytometry and Cytomorphological Approaches	Recruiting	NCT03469661
22	HVPG-guided Laparoscopic Versus Endoscopic Therapy for Variceal Rebleeding in Portal Hypertension: A Multicenter Randomized Controlled Trial (CHESS1803)	Recruiting	NCT03783065		Propranolol
23	Viral Hepatitis B and C Infection in Patients With Idiopathic Thrombocytopenic Purpura Treated With Triple Therapy	Not yet recruiting	NCT04113915		triple therapy;Steroids
24	Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder	Terminated	NCT00722254

Search NIH Clinical Center for Hypersplenism

Cochrane evidence based reviews: hypersplenism

Sources

Genetic Tests for Hypersplenism

Sources

Anatomical Context for Hypersplenism

MalaCards organs/tissues related to Hypersplenism:

⁴⁰

Liver, Spleen, Bone, Bone Marrow, Kidney, T Cells, Myeloid

Sources

Publications for Hypersplenism

Articles related to Hypersplenism:

(show top 50) (show all 2084)

#	Title	Authors	PMID	Year
1	Partial splenic embolization as pretreatment for antiviral therapy in hepatitis C virus infection. ⁶¹ ⁵⁴	Palsson B...Verbaan H	16215425	2005
2	Platelet count increase following phlebotomy in iron overloaded patients with liver cirrhosis. ⁶¹ ⁵⁴	Franchini M	12911944	2003
3	Role of elevated platelet-associated immunoglobulin G and hypersplenism in thrombocytopenia of chronic liver diseases. ⁶¹ ⁵⁴	Sanjo A...Suzuki N	12753144	2003
4	Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. ⁶¹ ⁵⁴	Giannini E...Testa R	12399221	2002
5	Role of plasma thrombopoietin level in thrombocytopenia of postoperative biliary atresia patients. ⁵⁴ ⁶¹	Hasegawa T...Okada A	12149701	2002
6	Thrombocytopenia associated with liver cirrhosis and hepatitis C viral infection: role of thrombopoietin. ⁶¹ ⁵⁴	Espanol I...Pujol-Moix N	11100362	2000
7	Thrombopoietin levels in serum and liver tissue in patients with chronic viral hepatitis and hepatocellular carcinoma. ⁶¹ ⁵⁴	Okubo M...Kawasaki H	11787473	2000
8	Laparoscopic cholecystectomy for cholelithiasis in patients with liver cirrhosis. ⁵⁴ ⁶¹	Ishikawa T...Nishiguchi Y	18493357	1995
9	Adverse Events Related to Partial Splenic Embolization for the Treatment of Hypersplenism: A Systematic Review. ⁶¹	Talwar A...Salem R	32014400	2020
10	Simultaneous radiofrequency ablation combined with laparoscopic splenectomy: a safe and effective way for patients with hepatocellular carcinoma complicated with cirrhosis and hypersplenism. ⁶¹	Jia Z...Wang Z	31116622	2020
11	Portal vein thrombosis in Fontan-associated liver disease. ⁶¹	Kaulitz R...Hofbeck M	32406357	2020
12	Patterns of splenic arterial enhancement on computed tomography scan are related to portal venous hypertension. ⁶¹	McCormick PA...Docherty JR	31490421	2020
13	Successful Simultaneous Anatomic Subtotal Splenectomy During Pediatric Living-Donor Liver Transplantation: A Case Report. ⁶¹	Zhou GP...Liu Y	32414607	2020
14	Partial Splenic Artery Embolization in 35 Cancer Patients: Results of a Single Institution Retrospective Study. ⁶¹	Kis B...Kim RD	31471193	2020
15	Sickle cell disease and malaria: decreased exposure and asplenia can modulate the risk from Plasmodium falciparum. ⁶¹	Mwaiswelo RO...Makani J	32334583	2020
16	Patterns of Comorbidity in Hepatocellular Carcinoma: A Network Perspective. ⁶¹	Mu XM...Feng J	32365650	2020
17	Clue to the cause of portal hypertension: Look at the raindrops. ⁶¹	Mishra S...Mandavdhare HS	32280785	2020
18	Significance of Amylase Monitoring in Peritoneal Drainage Fluid after Splenectomy: A Clinical Analysis of Splenectomy in 167 Patients with Hepatolenticular Degeneration. ⁶¹	Shen Y...Yu Q	32391757	2020
19	Durability of partial splenic artery embolization on platelet counts for cancer patients with hypersplenism-related thrombocytopenia. ⁶¹	Hill A...Sheth RA	32314004	2020
20	Thromboelastography Detects Possible Coagulation Disturbance in Pediatric Patients with Portal Cavernoma. ⁶¹	Wu L...Guo C	32355473	2020
21	[Quantitative assessment of hepatic and splenic blood flow status in patients with hypersplenism of different degrees based on multi-slice spiral CT whole-liver perfusion imaging]. ⁶¹	Gao YJ...Chen Y	32403885	2020
22	Interventions for preventing and managing advanced liver disease in cystic fibrosis. ⁶¹	Palaniappan SK...van Mourik I	32227478	2020
23	A Comparison of Splenic Pathologic Change and Immune Function in HBV-Related Portal Hypertension and Chinese Budd-Chiari Syndrome Patients with Hypersplenism. ⁶¹	Li S...Li Z	32101101	2020
24	Concomitant Existence of Paroxysmal Nocturnal Hemoglobinuria in a Patient with Hb E (HBB: c.79G>A) Trait. ⁶¹	Halder R...Pati HP	32354277	2020
25	Progressive Splenomegaly and Hypersplenism: An Unusual Case of Splenic Vein Stenosis with Histologic Findings of Hepatoportal Sclerosis. ⁶¹	Freiberg B...Valentino PL	31870607	2020
26	[Clinical efficacy of partial splenic arterial embolization in treatment of hypersplenism in patients with HBV-related cirrhosis]. ⁶¹	Wan P...Bai AP	32306663	2020
27	Combined Laparoscopic Splenectomy and Esophagogastric Devascularization versus Open Splenectomy and Esophagogastric Devascularization for Portal Hypertension due to Liver Cirrhosis. ⁶¹	Luo HP...Zhang WG	32166673	2020
28	Splenic serum from portal hypertensive patients enhances liver stem cell proliferation and self-renewal via the IGF-II/ERK signaling pathway. ⁶¹	Li J...Li Z	31495600	2020
29	FDG-PET/CT Demonstrates Splenic Angiosarcoma Bone Marrow Metastasis. ⁶¹	Takahashi H...Minami M	31306197	2020
30	Rapid increase of platelet counts during antiviral therapy in patients with hepatitis C virus infection. ⁶¹	Ishizu Y...Fujishiro M	31496023	2020
31	Atraumatic splenic rupture was attributed to intra-cystic haemorrhage and hypersplenism in a patient with cirrhosis and portal hypertension: A case report. ⁶¹	Li H...Sun S	32047630	2020
32	Severe Complications After Splenic Artery Embolization for Portal Hypertension Due to Hepatic Cirrhosis. ⁶¹	Zhang L...Zhang WG	32110126	2020
33	Comparison of early postoperative results between robot-assisted and laparoscopic splenectomy for non-traumatic splenic diseases rather than portal hypertensive hypersplenism-a meta-analysis. ⁶¹	Peng F...He P	31350089	2020
34	Isolated Splenic Lymphangiomas Presenting in an Infant with Isolated Anaemia. ⁶¹	Kakaje A...Hamdan O	32328111	2020
35	Recurrent kala-azar: report of two cured cases after total splenectomy. ⁶¹	Reinaldo LGC...Costa CHN	32491143	2020
36	Effects of laparoscopic splenectomy and azygoportal disconnection on liver synthesis function and cirrhosis: a 2-year prospective study. ⁶¹	Bai DS...Jiang GQ	31820157	2019
37	Distal Splenorenal Shunt (DSRS) in Children with Extrahepatic Portal Hypertension. ⁶¹	Rehman ZU...Nazir Z	31839103	2019
38	Investigation into imbalance of Th1/Th2 cells in cirrhotic, hypersplenic rats. ⁶¹	Lv Y...Deng J	31852338	2019
39	Improvement of human platelet aggregation post-splenectomy with paraesophagogastric devascularization in chronic hepatitis B patients with cirrhotic hypersplenism. ⁶¹	Zhang H...Li Z	31851564	2019
40	Novel Therapeutic Strategy Using Interventional Radiology (IVR) for Hepatitis C Virus (HCV)-Related Decompensated Liver Cirrhosis: A Case Report. ⁶¹	Iwamoto T...Sakaida I	31738743	2019
41	Impact of imbalanced graft-to-spleen volume ratio on outcomes following living donor liver transplantation in an era when simultaneous splenectomy is not typically indicated. ⁶¹	Yao S...Uemoto S	30830721	2019
42	Abnormal glucose metabolism in patients with Fontan circulation: Unique characteristics and associations with Fontan pathophysiology. ⁶¹	Ohuchi H...Nakai M	31425899	2019
43	Emergency or urgent splenectomy in children for non-traumatic reasons. ⁶¹	Samuk I...Freud E	31312939	2019
44	Endovascular treatment of surgical mesoportal and portosystemic shunt dysfunction in pediatric patients. ⁶¹	Stein EJ...Monroe EJ	31273428	2019
45	Clinical Characteristics and Risk Factors for Sinistral Portal Hypertension Associated with Moderate and Severe Acute Pancreatitis: A Seven-Year Single-Center Retrospective Study. ⁶¹	Li H...Tian F	31400275	2019
46	The Effects of Liver Transplantation in Children With Niemann-Pick Disease Type B. ⁶¹	Liu Y...Xia Q	30912297	2019
47	Etiology, presenting features and outcome of children with non-cirrhotic portal vein thrombosis: A multicentre national study. ⁶¹	Di Giorgio A...D'Antiga L	30928422	2019
48	Clinical features of idiopathic portal hypertension in China: A retrospective study of 338 patients and literature review. ⁶¹	Sun Y...Yang Z	30462857	2019
49	From sadness to stiffness: the spleen's progress. ⁶¹	Riva MA...Di Sabatino A	31152307	2019
50	Graft Hepatic Artery Rupture Due to Carbapenem-Resistant Klebsiella pneumoniae Infection After Liver Transplant. ⁶¹	Qian Y...Xia Q	31424357	2019

Sources

Genes for Hypersplenism

Genes related to Hypersplenism (0 elite genes):

(show all 20)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	F2	Coagulation Factor II, Thrombin	Protein Coding	19.81	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	18493357
2	THPO	Thrombopoietin	Protein Coding	15.37	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	12149701 12399221 12753144 (more) 11100362 11787473 12911944 16215425
3	ALB	Albumin	Protein Coding	13.61	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	EPO	Erythropoietin	Protein Coding	12.41	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	CD4	CD4 Molecule	Protein Coding	11.92	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	SERPINC1	Serpin Family C Member 1	Protein Coding	11.83	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	CSF3	Colony Stimulating Factor 3	Protein Coding	11.82	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	IFNG	Interferon Gamma	Protein Coding	11.17	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	TLR4	Toll Like Receptor 4	Protein Coding	10.7	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	CSF2	Colony Stimulating Factor 2	Protein Coding	10.45	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	IL4	Interleukin 4	Protein Coding	10.44	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	LTA	Lymphotoxin Alpha	Protein Coding	10.42	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	FOXP3	Forkhead Box P3	Protein Coding	10.32	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	PIK3R1	Phosphoinositide-3-Kinase Regulatory Subunit 1	Protein Coding	9.95	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	REL	REL Proto-Oncogene, NF-KB Subunit	Protein Coding	9.75	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	GPT	Glutamic--Pyruvic Transaminase	Protein Coding	6.72	DISEASES inferred ¹⁵
17	BMP6	Bone Morphogenetic Protein 6	Protein Coding	6.24	GeneCards inferred via : Publications (show sections)
18	EGF	Epidermal Growth Factor	Protein Coding	6.24	GeneCards inferred via : Publications (show sections)
19	IL2RA	Interleukin 2 Receptor Subunit Alpha	Protein Coding	6.24	GeneCards inferred via : Publications (show sections)
20	IL7R	Interleukin 7 Receptor	Protein Coding	6.24	GeneCards inferred via : Publications (show sections)

Sources

Variations for Hypersplenism

Sources

Expression for Hypersplenism

Search GEO for disease gene expression data for Hypersplenism.

Sources

Pathways for Hypersplenism

Pathways related to Hypersplenism according to GeneCards Suite gene sharing:

(show top 50) (show all 59)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁵ Show member pathways Immune System ⁶⁵ Neutrophil degranulation ⁶⁵	14.06	TLR4 REL PIK3R1 LTA IL7R IL4
2	ERK Signaling ⁶³ Show member pathways ILK Signaling ⁶³ MAPK Signaling ⁶³ Molecular Mechanisms of Cancer ⁶³ Rho Family GTPases ⁶³	13.85	THPO PIK3R1 LTA IL7R IL4 IL2RA
3	TGF-Beta Pathway ⁶³ Show member pathways JAK-STAT Pathway ⁶³ JNK Pathway ⁶³ MAPK Family Pathway ⁶³ Regulation of eIF4 and p70S6K ⁶³ SOCS Pathway ⁶³	13.51	THPO PIK3R1 LTA IL7R IL4 IL2RA
4	PEDF Induced Signaling ⁶³ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶³ Cytokine-cytokine receptor interaction ³⁶ Endothelin-1 Signaling Pathway ⁶³ Glucocorticoid Receptor Signaling ⁶³ IL-6 Pathway ⁶³ MIF Mediated Glucocorticoid Regulation ⁶³ MIF Regulation of Innate Immune Cells ⁶³ NFAT Signaling and Lymphocyte Interactions ⁶³ PGC1Alpha Pathway ⁶³ RAR-Gamma-RXR-Alpha Degradation ⁶³ STAT3 Pathway ⁶³	13.44	TLR4 THPO PIK3R1 LTA IL7R IL4
5	Cytokine Signaling in Immune system ⁶⁵ Show member pathways Signaling by Interleukins ⁶⁵	13.38	PIK3R1 LTA IL7R IL4 IL2RA IFNG
6	Response to elevated platelet cytosolic Ca2+ ⁶⁵ Show member pathways Disinhibition of SNARE formation ⁶⁵ Hemostasis ⁶⁵ Platelet activation, signaling and aggregation ⁶⁵ Platelet degranulation ⁶⁵	13.36	THPO SERPINC1 PIK3R1 IL2RA F2 EGF
7	Akt Signaling ⁶³ Show member pathways p38 Signaling ⁶³ Tec Kinases Signaling ⁶³	13.33	TLR4 THPO PIK3R1 LTA IL7R IL4
8	PAK Pathway ⁶³ Show member pathways Antioxidant Action of Vitamin-C ⁶³ Epithelial Adherens Junctions ⁶³	13.26	THPO PIK3R1 LTA IL7R IL4 IL2RA
9	p70S6K Signaling ⁶³ Show member pathways mTOR Pathway ⁶³ Renin-Angiotensin Pathway ⁶³	13.09	THPO PIK3R1 IL4 IL2RA F2 EGF
10	PI3K-Akt signaling pathway ³⁶ Show member pathways Human papillomavirus infection ³⁶	13.04	TLR4 PIK3R1 IL7R IL4 IL2RA EPO
11	Allograft rejection ¹ ³⁶ Show member pathways Antigen processing and presentation ³⁶ Asthma ³⁶ Autoimmune thyroid disease ³⁶ CTL Mediated Apoptosis ⁶³ Graft-versus-host disease ³⁶ Intestinal immune network for IgA production ³⁶ THC Differentiation Pathway ⁶³ Type I diabetes mellitus ³⁶ Viral myocarditis ³⁶	12.9	LTA IL4 IL2RA IFNG FOXP3 CD4
12	Pathways in cancer ³⁶	12.85	PIK3R1 IL7R IL4 IL2RA IFNG F2
13	Common Cytokine Receptor Gamma-Chain Family Signaling Pathways ⁶⁴ Show member pathways Adipocytokines and Insulin Signaling ⁶⁴ Development Thrombopoietin-regulated cell processes ²² IL-15 Signaling Pathways ⁶⁴ IL-2 Signaling Pathways ⁶⁴ IL-21 Signaling Pathways ⁶⁴ IL-4 Signaling Pathways ⁶⁴ IL-7 Signaling Pathways ⁶⁴ IL-9 Pathway ⁶³ IL-9 Signaling Pathways ⁶⁴ Immune response IL-9 signaling pathway ²²	12.82	THPO PIK3R1 LTA IL7R IL4 IL2RA
14	NF-KappaB Family Pathway ⁶³ Show member pathways NF-KappaB (p50-p65) Pathway ⁶³	12.74	TLR4 THPO REL PIK3R1 LTA EGF
15	4-1BB Pathway ⁶³ Show member pathways CD27 Pathway ⁶³ CD40 Signaling ⁶³ CMV and MAPK Pathways ⁶³ NF-KappaB Activation by EBV ⁶³ NF-kappaB Activation by Viruses ⁶³ PKR Pathway ⁶³ SUMO Pathway ⁶³ TNFR2 Pathway ⁶³	12.7	REL PIK3R1 LTA IFNG EGF CD4
16	Immune response NFAT in immune response ²² Show member pathways Immune response CD28 signaling ²² Immune response ICOS pathway in T-helper cell ²² Immune response T cell receptor signaling pathway ²²	12.68	REL PIK3R1 IL4 IL2RA IFNG CD4
17	Th17 cell differentiation ³⁶ Show member pathways IL-22 Pathway ⁶³ Immune response IL-22 signaling pathway ²² Inflammatory bowel disease (IBD) ³⁶ Th1 and Th2 cell differentiation ³⁶	12.64	TLR4 IL4 IL2RA IFNG FOXP3 CD4
18	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶³ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²² Rac1/Pak1/p38/MMP-2 pathway ¹	12.63	REL PIK3R1 IFNG F2 CD4
19	NF-kappaB Signaling ⁴	12.6	REL IL4 IL2RA IFNG FOXP3
20	T cell receptor signaling pathway ³⁶ Show member pathways PD-L1 expression and PD-1 checkpoint pathway in cancer ³⁶ T-Cell antigen Receptor (TCR) Signaling Pathway ¹ T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection ¹	12.58	TLR4 REL PIK3R1 IL4 IFNG EGF
21	Human T-cell leukemia virus 1 infection ³⁶	12.39	PIK3R1 LTA IL2RA CSF2 CD4
22	IL-17 Family Signaling Pathways ⁶⁴ Show member pathways IL17 signaling pathway ¹ IL-17 signaling pathway ³⁶ Interleukin-17 signaling ⁶⁵ Mucin expression in CF via IL-6, IL-17 signaling pathways ²²	12.38	REL IL4 IFNG CSF3 CSF2
23	Folate Metabolism ¹ Show member pathways Selenium Micronutrient Network ¹ thioredoxin pathway ¹ Vitamin B12 Metabolism ¹	12.36	IL4 IFNG F2 ALB
24	Immune response IFN alpha/beta signaling pathway ²² Show member pathways Cytokine Network ⁶³ Interferon alpha/beta signaling ⁶⁵ Regulation of IFNA signaling ⁶⁵	12.3	THPO LTA IL4 IL2RA IFNG BMP6
25	JAK-STAT signaling pathway ³⁶ Show member pathways B-Cell Development ⁶³ IL-7 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁴ Interleukin-19, 20, 22, 24 ⁶⁵ Jak/STAT Signaling Pathway ⁶⁴ Type III interferon signaling ¹	12.25	THPO PIK3R1 IL7R IL4 IL2RA IFNG
26	Colorectal Cancer Metastasis ⁶³	12.23	TLR4 PIK3R1 IFNG EGF
27	Bacterial infections in CF airways ²² Show member pathways IL-1 beta-dependent CFTR expression ²² Immune response Bacterial infections in normal airways ²² Immune response TLR signaling pathways ²²	12.22	TLR4 REL IL4 IFNG
28	Jak Stat Signaling Pathway ⁶⁶ Show member pathways Commom Cytokine Receptor G Chain Siganaling Pathway ⁶⁶	12.16	PIK3R1 IL7R IL4 IL2RA
29	IL12-mediated signaling events ¹ Show member pathways Immune response IL-12-induced IFN-gamma production ²²	12.06	REL IL4 IL2RA IFNG CD4
30	HIF-1 signaling pathway ³⁶	12.03	TLR4 PIK3R1 IFNG EPO EGF
31	IL27-mediated signaling events ¹ Show member pathways IL12 Signaling Pathway ⁶⁶ Th1 Differentiation ⁶⁴	12	TLR4 LTA IFNG CD4
32	Amoebiasis ³⁶	11.98	TLR4 PIK3R1 IFNG CSF2
33	Th17 Differentiation ⁶⁴ Show member pathways IL-21 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁴	11.92	TLR4 IL4 IFNG CD4
34	Cytokine production by Th17 cells in CF (Mouse model) ²² Show member pathways Cytokine production by Th17 cells in CF ²²	11.92	TLR4 REL FOXP3 CSF3 CSF2
35	Calcineurin-regulated NFAT-dependent transcription in lymphocytes ¹ Show member pathways Calcium signaling in the CD4+ TCR pathway ¹	11.82	IL4 IL2RA IFNG FOXP3 CSF2
36	Glucocorticoid receptor regulatory network ¹	11.81	IL4 IFNG CSF2
37	Dendritic Cells Developmental Lineage Pathway ⁶⁴	11.81	IL7R IFNG CSF2 CD4
38	Innate Lymphoid Cells Differentiation ⁶⁴	11.75	LTA IL7R IL4 IL2RA IFNG CD4
39	IL2 signaling events mediated by PI3K ¹ Show member pathways IL2 signaling events mediated by STAT5 ¹	11.73	PIK3R1 LTA IL4 IL2RA FOXP3
40	Lung fibrosis ¹	11.71	IL4 EGF CSF3 CSF2
41	Photodynamic therapy-induced NF-kB survival signaling ¹ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.7	REL IFNG CSF2
42	IL4-mediated signaling events ¹	11.69	PIK3R1 LTA IL4
43	Transcription_NF-kB signaling pathway ²²	11.62	TLR4 REL LTA
44	Cellular Transformation by HTLV1 ⁶³ Show member pathways Activation of NF-KappaB by PKR ⁶³	11.6	REL LTA IFNG
45	Malaria ³⁶	11.59	TLR4 IFNG CSF3
46	Interleukin-10 signaling ⁶⁵	11.58	IL4 CSF3 CSF2
47	MSP-RON Signaling ⁶³	11.56	TLR4 PIK3R1 IFNG
48	Hematopoietic Stem Cell Differentiation ¹	11.56	EPO CSF3 CSF2
49	Hematopoietic cell lineage ³⁶	11.55	THPO IL7R IL4 IL2RA EPO CSF3
50	Th2 Differentiation ⁶⁴	11.54	IL4 IL2RA IFNG FOXP3 CD4

Sources

GO Terms for Hypersplenism

Cellular components related to Hypersplenism according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	9.77	THPO SERPINC1 LTA IL7R IL4 IFNG
2	external side of plasma membrane	GO:0009897	9.55	TLR4 IL7R IL2RA F2 CD4
3	extracellular space	GO:0005615	9.44	THPO SERPINC1 LTA IL4 IFNG GPT
4	clathrin-coated vesicle membrane	GO:0030665	9.43	IL7R EGF CD4

Biological processes related to Hypersplenism according to GeneCards Suite gene sharing:

(show all 31)

#	Name	GO ID	Score	Top Affiliating Genes
1	signal transduction	GO:0007165	10.22	TLR4 THPO PIK3R1 LTA IL7R IL4
2	positive regulation of transcription by RNA polymerase II	GO:0045944	10.18	TLR4 REL PIK3R1 IL4 FOXP3 CSF3
3	positive regulation of transcription, DNA-templated	GO:0045893	10.04	REL IL4 FOXP3 EPO EGF CD4
4	cell surface receptor signaling pathway	GO:0007166	9.95	IL7R IL2RA IFNG F2 CD4
5	positive regulation of ERK1 and ERK2 cascade	GO:0070374	9.94	TLR4 THPO EPO CD4
6	positive regulation of protein phosphorylation	GO:0001934	9.92	THPO IFNG F2 CD4
7	positive regulation of protein kinase B signaling	GO:0051897	9.91	THPO PIK3R1 EGF CSF3
8	response to nutrient	GO:0007584	9.83	SERPINC1 LTA EPO
9	positive regulation of peptidyl-tyrosine phosphorylation	GO:0050731	9.81	EGF CSF3 CD4 BMP6
10	negative regulation of neuron death	GO:1901215	9.8	REL EPO CSF3
11	positive regulation of T cell proliferation	GO:0042102	9.8	IL4 IL2RA CD4
12	cytokine-mediated signaling pathway	GO:0019221	9.8	PIK3R1 IL4 IL2RA CSF3 CSF2 CD4
13	positive regulation of phosphatidylinositol 3-kinase signaling	GO:0014068	9.78	PIK3R1 F2 EPO CSF3
14	T cell activation	GO:0042110	9.77	IL4 FOXP3 CD4
15	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	9.76	IL4 IFNG EPO CSF2
16	positive regulation of gene expression	GO:0010628	9.76	TLR4 IL7R IL4 IFNG FOXP3 EGF
17	negative regulation of osteoclast differentiation	GO:0045671	9.71	TLR4 PIK3R1 IL4
18	macrophage differentiation	GO:0030225	9.67	IFNG CSF2 CD4
19	negative regulation of T-helper 17 cell differentiation	GO:2000320	9.65	IL4 FOXP3
20	positive regulation of cell proliferation	GO:0008284	9.65	THPO IL7R IL4 IFNG F2 EPO
21	cellular response to granulocyte macrophage colony-stimulating factor stimulus	GO:0097011	9.64	CSF2 CD4
22	negative regulation of lymphocyte proliferation	GO:0050672	9.61	IL2RA FOXP3
23	regulation of regulatory T cell differentiation	GO:0045589	9.61	IL2RA IFNG FOXP3
24	positive regulation of cellular respiration	GO:1901857	9.59	IL4 IFNG
25	neuroinflammatory response	GO:0150076	9.58	IL4 IFNG
26	positive regulation of interleukin-23 production	GO:0032747	9.58	IFNG CSF2
27	negative regulation of interleukin-17 production	GO:0032700	9.58	TLR4 IFNG FOXP3
28	negative regulation of chronic inflammatory response	GO:0002677	9.56	IL4 FOXP3
29	macrophage activation	GO:0042116	9.54	TLR4 IL4 CSF2
30	positive regulation of MHC class II biosynthetic process	GO:0045348	9.43	TLR4 IL4 IFNG
31	immune response	GO:0006955	9.32	TLR4 LTA IL7R IL4 IL2RA IFNG

Molecular functions related to Hypersplenism according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	signaling receptor binding	GO:0005102	9.55	TLR4 THPO LTA F2 CD4
2	growth factor activity	GO:0008083	9.5	THPO IL4 F2 EGF CSF3 CSF2
3	cytokine activity	GO:0005125	9.23	THPO LTA IL4 IFNG EPO CSF3

Sources

Sources for Hypersplenism

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia